Elemento Lab

Publications

Found 420 results
Filters: First Letter Of Last Name is S  [Clear All Filters]
2021
Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.
Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.
Zoughbi WAl, Kim D, Alperstein SAnn, Ohara K, Manohar J, Greco N, Khani F, Robinson BD, Rao RA, Elemento O et al..  2021.  Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience.. Cancer Cytopathol.
Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.
Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.
Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.
Kaya C, Dorsaint P, Mercurio S, Campbell AM, Eng KWha, Nikiforova MN, Elemento O, Nikiforov YE, Sboner A.  2021.  Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples.. Thyroid. 31(4):589-595.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.
Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)
Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)
Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)
Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)
Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)
Dixon G, Pan H, Yang D, Rosen BP, Jashari T, Verma N, Pulecio J, Caspi I, Lee K, Stransky S et al..  2021.  QSER1 protects DNA methylation valleys from de novo methylation.. Science. 372(6538)
Dixon G, Pan H, Yang D, Rosen BP, Jashari T, Verma N, Pulecio J, Caspi I, Lee K, Stransky S et al..  2021.  QSER1 protects DNA methylation valleys from de novo methylation.. Science. 372(6538)
Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR et al..  2021.  Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.. Nat Immunol. 22(2):240-253.
Manohar J, Abedian S, Martini R, Kulm S, Salvatore M, Ho K, Christos P, Campion T, Imperato-McGinley J, Ibrahim S et al..  2021.  Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter.. medRxiv.
Manohar J, Abedian S, Martini R, Kulm S, Salvatore M, Ho K, Christos P, Campion T, Imperato-McGinley J, Ibrahim S et al..  2021.  Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter.. medRxiv.
Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, Park J, Foox J, Hether T, Warren S et al..  2021.  The spatial landscape of lung pathology during COVID-19 progression.. Nature. 593(7860):564-569.
Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, Park J, Foox J, Hether T, Warren S et al..  2021.  The spatial landscape of lung pathology during COVID-19 progression.. Nature. 593(7860):564-569.
Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, Park J, Foox J, Hether T, Warren S et al..  2021.  The spatial landscape of lung pathology during COVID-19 progression.. Nature. 593(7860):564-569.